Business
Business and Trading Update
Business and Trading Update.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 5833F Shield Therapeutics PLC 22 February 2018 \n\nThis announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 \nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\nBusiness and Trading Update\nChange of results date for the year ended 31 December 2017 \n- Revenues for the year ended 31 December 2017 expected to be £637,000 (2016: £304,000), in line with Board expectations \n- Year-end unaudited cash position was £13.3m (2016: £21.0m)\n- Cost rationalisation programme being implemented\n- Current cash runway extended to at least the end of Q4 2018\n- Board leading a full review of Shield's strategic options\n- Feraccru remains commercially available through Shield Therapeutics and it European partners, with more patients than ever being treated \n- Detailed analysis of the AEGIS-CKD pivotal Phase III full dataset underway and expected to be complete before the end of March 2018\n- Results for the year ended 31 December 2017 will be announced on 11 April 2018\n \nLondon, UK, 22 February 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing iron deficiency anaemia, today announces a business update, a brief trading update for the year ended 31 December 2017 and confirmation that the Board has initiated a full review of the Company's strategic options. Feraccru, the Company's lead asset, is approved and marketed in Europe for the treatment of iron deficiency anemia (IDA), initially in patients with inflammatory bowel disease (IBD). \n \nTrading update for year ended 31 December 2017:\nTrading for FY 2017 was in line with Board expectations and 2018 trading started positively. Revenues for the 12 months ended 31 December 2017 are expected to be £637,000 (2016: £304,000) with more patients than ever being treated with Feraccru. At the year end the Company's unaudited cash position was £13.3m (2016: £21.0m).\n \nBusiness update:\nFollowing announcement of the unexpected and disappointing initial top-line results from the AEGIS-CKD pivota...